Related Articles
The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression‑free survival in patients with advanced EGFR‑mutated NSCLC
Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment
Predictive value of inflammatory indexes on the chemotherapeutic response in patients with unresectable lung cancer: A retrospective study
Prognostic value of the pretreatment neutrophil‑to‑lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure
Role of combining neutrophil‑to‑lymphocyte ratio and pretreatment body mass index in predicting progression‑free survival in patients with non‑small cell lung cancer treated with nivolumab